06.09.2018
MorphoSys AG DE0006632003
DGAP-News: MorphoSys AG to be listed in MDAX
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous
MorphoSys AG to be listed in MDAX (news with additional features)
06.09.2018 / 10:01
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg/Munich, Germany, September 6, 2018
MorphoSys AG to be listed in MDAX
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR)
announced today that its shares will be included in the MDAX as of September
24, 2018 as announced by Deutsche Börse. The MorphoSys shares will remain
part of the TecDAX segment, to which they have belonged since 2004.
The simultaneous inclusion in both indices, MDAX and TecDAX, is based on the
reorganization of the index rules of Deutsche Börse, which will come into
force on September 24, 2018. The existing separation into the Tech and
Classic segments has been removed. Thus companies listed in the DAX, which
are assigned to the technology sectors, can now also be included in the
TecDAX. Accordingly, TecDAX stocks can be listed in the DAX, the MDAX or the
SDAX based on purely quantitative criteria relating to market capitalization
and trading volume. MorphoSys qualifies for inclusion in the MDAX by
fulfilling both of these criteria.
In the future, the TecDAX will comprise the 30 largest companies measured by
market capitalization and turnover with a focus on technology. The MDAX will
track the 60 largest companies on the German stock market behind the DAX
index, which will continue to cover the 30 largest stocks in Germany.
About MorphoSys
MorphoSys is a late-stage, biopharmaceutical company devoted to the
development of innovative and differentiated therapies for patients
suffering from serious diseases. Based on its technological leadership in
generating antibodies, MorphoSys, together with its partners, has developed
and contributed to the development of more than 100 product candidates, of
which 29 are currently in clinical development. This broad pipeline spans
MorphoSys's two business segments: Proprietary Development, in which the
Company invests in product candidates for its own account, and Partnered
Discovery, in which product candidates are developed exclusively for a
variety of Pharma and Biotech partners. In 2017, Tremfya(R) (guselkumab),
marketed by Janssen, became the first therapeutic antibody based on
MorphoSys's proprietary technology to receive marketing approval for the
treatment of moderate to severe plaque psoriasis in the United States, the
European Union and Canada. MorphoSys is listed on the Frankfurt Stock
Exchange and on the U.S. stock exchange Nasdaq, under the symbol MOR. For
regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R),
Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R)
and LanthioPep(R) are registered trademarks of the MorphoSys Group.
Tremfya(R)
is a trademark of Janssen Biotech, Inc.
MorphoSys forward looking statements
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies, including the transition of MorphoSys to a
fully integrated biopharmaceutical company. The forward-looking statements
contained herein represent the judgment of MorphoSys as of the date of this
release and involve known and unknown risks and uncertainties, which might
cause the actual results, financial condition and liquidity, performance or
achievements of MorphoSys, or industry results, to be materially different
from any historic or future results, financial conditions and liquidity,
performance or achievements expressed or implied by such forward-looking
statements. In addition, even if MorphoSys' results, performance, financial
condition and liquidity, and the development of the industry in which it
operates are consistent with such forward-looking statements, they may not
be predictive of results or developments in future periods. Among the
factors that may result in differences are that MorphoSys' expectations
regarding its 2018 results of operations may be incorrect, MorphoSys'
expectations regarding its development programs may be incorrect, the
inherent uncertainties associated with competitive developments, clinical
trial and product development activities and regulatory approval
requirements (including that MorphoSys may fail to obtain regulatory
approval for MOR208 and that data from MorphoSys' ongoing clinical research
programs may not support registration or further development of its product
candidates due to safety, efficacy or other reasons), MorphoSys' reliance on
collaborations with third parties, estimating the commercial potential of
its development programs and other risks indicated in the risk factors
included in MorphoSys's Registration Statement on Form F-1 and other filings
with the US Securities and Exchange Commission. Given these uncertainties,
the reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. MorphoSys expressly disclaims
any obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard thereto or
any change in events, conditions or circumstances on which any such
statement is based or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements, unless
specifically required by law or regulation.
For more information, please contact:
MorphoSys AG
Alexandra Goller
Associate Director Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Dr. Claudia Gutjahr-Löser
Investor Relations Officer
Tel: +49 (0) 89 / 899 27-404
[email protected]
---------------------------------------------------------------------------
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=MYRCAGECIW
Document title: Media Release
---------------------------------------------------------------------------
06.09.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: [email protected]
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
721149 06.09.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
MorphoSys AG ISIN: DE0006632003 können Sie bei EQS abrufen
Biotechnologie , 663200 , MOR , XETR:MOR